NeuroBo shareholders holds 96.24% stake in the firm. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. E-mail Address. AGREEMENT AND PLAN OF MERGER AND REORGANIZATION. January 10, 2020. in Buzz. Posted on 01/10/2020 342 . NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics. As previously announced, Gemphire’s stockholders voted to approve the proposals required to complete the merger transaction. Gemphire Therapeutics has agreed to merge with biotechnology company NeuroBo Pharmaceuticals in an all-stock transaction. ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) — The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is … As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the … The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions. January 10, 2020, 5:00 PM NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo … 371 28. THIS FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “First Amendment”) is entered into and made effective as of October 29, 2019 (the “Effective Date”), by and among GEMPHIRE THERAPEUTICS INC., a Delaware corporation (“Parent”), GR MERGER SUB INC., a … The move comes as NeuroBo plans to start a … BOSTON--(BUSINESS WIRE)--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo … NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on … After the merger, NeuroBo investors will own 95.94% of the new company, while Gemphire shareholders will own around 4.06%. FIRST AMENDMENT TO. The pending merger between Gemphire Therapeutics Inc. (GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions. The pending merger between Gemphire Therapeutics Inc. (NASDAQ: GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, … NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. 13 January 2020 (Last Updated January 13th, 2020 10:39) NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019.The new combined company, known as NeuroBo … Exhibit 2.1 . On a pro forma basis and based upon the number of shares of Gemphire common stock to be issued in the merger, the pre-merger Gemphire shareholders will own approximately 4.06% of the post-merger combined company and the pre-merger NeuroBo investors will own approximately 95.94% of the post-merger combined company on a fully-diluted basis. Gemphire Therapeutics Inc. and Boston-based NeuroBo Pharmaceuticals Inc. have agreed to a deal that will result in Gemphire changing its name to NeuroBo Pharmaceuticals. Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company, Stocks: GEMP, release date:Jul 24, 2019 by admin. BOSTON--(BUSINESS WIRE)--Jan 10, 2020--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals PRESS RELEASE GlobeNewswire Dec. 6, 2019, 08:42 AM Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., ("NeuroBo") and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Article Stock Quotes (2) Comments (0) FREE Breaking News Alerts from StreetInsider.com! The merged company will focus on the development of NeuroBo’s clinical-stage drug candidates for the treatment of neurodegenerative diseases. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Read full article. Posted on 07/24/2019 56 The merger has been completed between NeuroBo Pharmaceuticals and Gemphire Therapeutics (Credit: Akshay93 from Pixabay) Subscribe to our email newsletter The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the … ... NeuroBo Pharmaceuticals complete Gemphire merger. Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals, Stocks: GEMP,NRBO, release date:Dec 30, 2019 NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. The merged firm will advance NeuroBo’s clinical-stage drug candidates for neurodegenerative disorders.